- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.10. | Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal | ||
| 28.10. | FDA grants orphan drug status to Octant's OCT-980 for RP | ||
| 28.10. | Arrowhead gains UK marketing authorisation for Redemplo | ||
| 28.10. | Anthropic plots IPO amid ongoing foray into drug development | ||
| 27.10. | Pfizer's prostate cancer combo moves to earlier line on expanded US approval | ||
| 27.10. | Regeneron agrees to $270m extension to supply Ebola medicine in US | ||
| 27.10. | China's NMPA accepts Innovent application for sintilimab combo | ||
| 26.10. | UK biotech poised for record VC year after maintaining recovery momentum | ||
| 26.10. | Lunit and Summit to evaluate pathology platform for tumour analysis | ||
| 26.10. | Pathos AI completes $237m Series E round to expand oncology pipeline | ||
| 23.10. | US targets Chinese biotech investment, but licensing deals remain exempt | ||
| 23.10. | Gilead spends $1.28bn on PepStar's potential Icotyde rival | ||
| 23.10. | Boehringer and Microsoft collaborate to explore AI in clinical research | ||
| 23.10. | Celltrion and Kaigene sign $580m licence deal for KG013 | ||
| 22.10. | Roche's pharma sales grow 7% but pipeline trimmed down | ||
| 22.10. | AstraZeneca bags another US indication for Ultomiris with IgAN approval | ||
| 22.10. | Astellas and AI Proteins sign miniprotein therapeutics deal | ||
| 22.10. | MSD's Keytruda and Padcev combination receives EC approval | ||
| 21.10. | FDA approves GSK's Hibsago as first functional cure for hepatitis B | ||
| 21.10. | AbbVie races into F1 as pharma companies continue push into sport | ||
| 21.10. | FDA approves Cosette's Evoxac oral solution for Sjögren's disease | ||
| 21.10. | MHRA revokes approval for Valneva's Ixchiq due to safety frailties | ||
| 21.10. | Sanofi and ScionxBio partner on mRNA therapies | ||
| 20.10. | EyePoint halves workforce and ends Phase III trial early after endpoint miss | ||
| 20.10. | Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.